Navigation Links
Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2012
Date:1/26/2012

UNION CITY, Calif., Jan. 26, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2011.

Record quarterly highlights include:

  • Medical market sales of $8.1 million, up $21,000 over last year's comparable quarter.
  • Total medical reagent disc sales of $5.6 million, up 8% over last year's comparable quarter.
  • Total medical reagent disc sales of 655,000 units, up 14% over last year's comparable quarter.

  • Other quarterly highlights include:

  • North America revenues of $31.8 million, up 6% over last year's comparable quarter.
  • Veterinary market sales of $28.5 million, up 8% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of $20.4 million, up 5% over last year's comparable quarter.
  • Total medical and veterinary reagent disc sales of 1.6 million units, up 5% over last year's comparable quarter.

  • Quarterly Results:  For the fiscal quarter ended December 31, 2011, Abaxis reported revenues of $37.9 million, as compared with revenues of $35.9 million for the comparable period last year, an increase of 5 percent.
    Revenues from instruments, which include chemistry analyzers, hematology instruments, VSpro coagulation and specialty analyzers and i-STAT analyzers, decreased by an aggregate of $210,000 or 2 percent, over the same period last year.  Revenues from consumables, which include reagent discs, hematology reagent kits, VSpro coagulation and specialty cartridges, i-STAT cartridges and rapid tests, increased by an aggregate of $2.3 million, or 9 percent, over the same period last year.
    Abaxis reported net income of $2.9 million for the fiscal quarter ended December 31, 2011, compared to $3.8 million for the same period last year, a decrease of 26 percent.
    Abaxis' effective tax rate in the quarter ended December 31, 2011 was 37 percent, compared to 35 percent for the same period last year.
    Abaxis reported diluted net income per share of $0.13 (calculated based on 21,990,000 shares) for the three-month period ended December 31, 2011, compared to $0.17 per share (calculated based on 22,872,000 shares) for the same period last year.

    Nine-Month Results:  For the nine-month period ended December 31, 2011, Abaxis reported revenues of $113.9 million, as compared with revenues of $106.1 million for the comparable period last year, an increase of 7 percent.
    Revenues from instrument sales increased by an aggregate of $1.1 million, or 5 percent, over the same period last year.
    Revenues from consumables increased by an aggregate of $7.9 million, or 10 percent, over the same period last year.
    The company reported net income of $8.4 million, compared to $11.2 million for the same period last year, a decrease of 25 percent.
    The company's effective tax rate in the nine-month period ended December 31, 2011, was 37 percent, compared to 38 percent for the same period last year.  The company reported diluted net income per share of $0.37 (calculated based on 22,579,000 shares) for the nine-month period ended December 31, 2011, compared to $0.49 per share (calculated based on 22,795,000 shares) for the same period last year.

    Other Reported Information:  Total sales in the medical market for the third quarter of fiscal 2012 were $8.1 million, which were flat, compared to the same period last year.  Medical sales worldwide, excluding sales to the U.S. government, during the third quarter of fiscal 2012 were $7.5 million, an increase of 15 percent, compared to the same period last year.  Total sales in the veterinary market for the third quarter of fiscal 2012 were $28.5 million, an increase of 8 percent, compared to the same period last year.  Veterinary reagent disc sales for the third quarter of fiscal 2012 were $14.7 million, an increase of 3 percent compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the third quarter of fiscal 2012 was $1.5 million, compared to $1.3 million for the same period last year.  Abaxis' Board of Directors has approved a $15.0 million increase to its existing share repurchase program, to a total of $55.0 million.  

    Clint Severson, chairman and chief executive officer of Abaxis, commented, "Veterinary market revenues for the quarter increased 8% despite the lingering economic slowdown in our European markets and distributor inventory adjustment due to the establishment of our own warehouse near Frankfurt to provide distributors with support in a more timely manner.  We expect to see a more stable business environment in our European markets in the coming quarters.  Although we clearly faced various challenging conditions in the third fiscal quarter, we continued to grow total revenues at a rate of 5% compared to the same quarter last year.  Medical market reagent disc unit sales during the quarter were a record of 655,000 units, up 14% versus the comparable quarter last year.  We believe this is a reliable indication that we are developing a solid position in this critical market and we are doing it on a consistent basis."

    "We continue to make strategic investments for the future growth of our business," continued Mr. Severson.  "We are in the process of adding to our sales force, both in the U.S. and Europe, to develop expanded market share in those markets.  We are continuing to invest in our new Abaxis Veterinary Reference Laboratories (AVRL) to position it as the leading outsourced laboratory provider featuring tighter test turnarounds, superior customer service, and cost efficiencies not available at the AVRL's competitors.  We believe this is an important business segment with the potential of significant returns in the coming years."

    Conference CallAbaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Thursday, January 26, 2012.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com.  A replay of the call will be available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10008894, through February 1, 2012.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.  

    About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).

    Use of Financial MeasuresTo supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure.  The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.  For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

    This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2011 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Financial Tables on Following PagesABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedNine Months EndedDecember 31,December 31,2011201020112010Revenues

    $
    37,850

    $
    35,906

    $
    3,878

    $
    ,136Cost of revenues

    17,372

    16,097

    52,156

    46,793Gross profit

    20,478

    19,809

    61,722

    59,343Operating expenses:   Research and development

    2,634

    2,947

    9,096

    9,321   Sales and marketing

    9,927

    8,208

    28,414

    25,249   General and administrative

    3,280

    2,820

    11,194

    7,596Total operating expenses

    15,841

    13,975

    48,704

    42,166Income from operations

    4,637

    5,834

    13,018

    17,177Interest and other income (expense), net

    (91)

    46

    259

    698Income before income tax provision

    4,546

    5,880

    13,277

    17,875Income tax provision

    1,696

    2,045

    4,892

    6,711Net income

    $
    2,850

    $
    3,835

    $
    8,385

    $
    ,164Net income per share:   Basic net income per share

    $
    .13

    $
    .17

    $
    .38

    $
    .50   Diluted net income per share

    $
    .13

    $
    .17

    $
    .37

    $
    .49Shares used in the calculation of net income per share:   Weighted average common shares outstanding - basic

    21,672

    22,398

    22,213

    22,309   Weighted average common shares outstanding - diluted

    21,990

    22,872

    22,579

    22,795ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)December 31,March 31,20112011Current assets:   Cash and cash equivalents

    $
    35,368

    $
    43,471   Short-term investments

    22,366

    25,981   Receivables, net

    26,041

    27,880   Inventories

    19,852

    19,814   Prepaid expenses and other current assets

    5,600

    3,496   Net deferred tax assets, current

    3,166

    3,422Total current assets

    112,393

    124,064   Long-term investments

    30,189

    36,237   Investment in unconsolidated affiliate

    2,668

    2,769   Property and equipment, net

    23,448

    19,637   Intangible assets, net

    4,148

    4,216   Net deferred tax assets, non-current

    1,080

    1,203   Other assets

    106

    134Total assets

    $
    74,032

    $
    88,260Current liabilities:   Accounts payable

    $
    ,245

    $
    ,173   Accrued payroll and related expenses

    5,747

    6,129   Accrued taxes

    -

    559   Other accrued liabilities

    2,072

    1,677   Deferred revenue

    1,138

    953   Warranty reserve

    1,123

    1,031Total current liabilities

    16,325

    16,522Non-current liabilities:   Deferred rent

    597

    416   Deferred revenue

    2,285

    1,737   Warranty reserve

    482

    191   Notes payable, less current portion

    808

    746Total non-current liabilities

    4,172

    3,090Total liabilities

    20,497

    19,612Shareholders' equity:   Common stock

    108,558

    132,042   Retained earnings

    44,991

    36,606   Accumulated other comprehensive loss

    (14)

    -Total shareholders' equity

    153,535

    168,648Total liabilities and shareholders' equity

    $
    74,032

    $
    88,260Operating Income Per Share(In thousands, except per share data)Three Months EndedNine Months EndedDecember 31,December 31,2011201020112010Shares used in the calculation of operating income per share:Weighted average common shares outstanding - basic

    21,672

    22,398

    22,213

    22,309Weighted average common shares outstanding - diluted

    21,990

    22,872

    22,579

    22,795Operating income per share - basic

    $
    .21

    $
    .26

    $
    .59

    $
    .77Operating income per share - diluted

    $
    .21

    $
    .26

    $
    .58

    $
    .75Revenues by Geographic Region(In thousands)Three Months EndedNine Months EndedDecember 31,December 31,2011201020112010North America

    $
    31,847

    $
    30,068

    $
    93,540

    $
    87,385International

    6,003

    5,838

    20,338

    18,751Total revenues

    $
    37,850

    $
    35,906

    $
    3,878

    $
    ,136Revenues by Customer Group(In thousands)Three Months EndedNine Months EndedDecember 31,December 31,2011201020112010Medical Market

    $
    8,147

    $
    8,126

    $
    22,636

    $
    21,421Veterinary Market

    28,467

    26,283

    87,684

    79,750Other

    1,236

    1,497

    3,558

    4,965Total revenues

    $
    37,850

    $
    35,906

    $
    3,878

    $
    ,136
    '/>"/>

    SOURCE Abaxis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
    2. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
    3. Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010
    4. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
    5. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
    7. Abaxis to Report Second Quarter Fiscal 2011 Financial Results Tuesday, October 26, 2010
    8. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
    9. Abaxis, Inc. to Present at Stephens Fall Investment Conference
    10. Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus
    11. Abaxis to Report Third Quarter Fiscal 2011 Financial Results Thursday, January 27, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
    (Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
    (Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
    (Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
    (Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
    (Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
    Breaking Medicine News(10 mins):